Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) EV-to-Revenue : 2.01 (As of Jun. 24, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Zhejiang East-Asia Pharmaceutical Co EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Zhejiang East-Asia Pharmaceutical Co's enterprise value is ¥2,686 Mil. Zhejiang East-Asia Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ¥1,339 Mil. Therefore, Zhejiang East-Asia Pharmaceutical Co's EV-to-Revenue for today is 2.01.

The historical rank and industry rank for Zhejiang East-Asia Pharmaceutical Co's EV-to-Revenue or its related term are showing as below:

SHSE:605177' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.57 Med: 2.43 Max: 4.78
Current: 1.93

During the past 8 years, the highest EV-to-Revenue of Zhejiang East-Asia Pharmaceutical Co was 4.78. The lowest was 1.57. And the median was 2.43.

SHSE:605177's EV-to-Revenue is ranked better than
79.11% of 1034 companies
in the Biotechnology industry
Industry Median: 7.69 vs SHSE:605177: 1.93

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-24), Zhejiang East-Asia Pharmaceutical Co's stock price is ¥21.56. Zhejiang East-Asia Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was ¥10.09. Therefore, Zhejiang East-Asia Pharmaceutical Co's PS Ratio for today is 2.14.

Zhejiang East-Asia Pharmaceutical Co EV-to-Revenue Historical Data

The historical data trend for Zhejiang East-Asia Pharmaceutical Co's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang East-Asia Pharmaceutical Co EV-to-Revenue Chart

Zhejiang East-Asia Pharmaceutical Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

3.46

3.56

1.58

2.21

Zhejiang East-Asia Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial															1.92	1.99	2.28	2.21	1.83

Competitive Comparison of Zhejiang East-Asia Pharmaceutical Co's EV-to-Revenue

For the Biotechnology subindustry, Zhejiang East-Asia Pharmaceutical Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zhejiang East-Asia Pharmaceutical Co's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zhejiang East-Asia Pharmaceutical Co's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Zhejiang East-Asia Pharmaceutical Co's EV-to-Revenue falls into.

Zhejiang East-Asia Pharmaceutical Co EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Zhejiang East-Asia Pharmaceutical Co's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	2685.738	/	1339.329
	=	2.01

Zhejiang East-Asia Pharmaceutical Co's current Enterprise Value is ¥2,686 Mil.
Zhejiang East-Asia Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,339 Mil.

Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Zhejiang East-Asia Pharmaceutical Co's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	21.56	/	10.086
	=	2.14

Zhejiang East-Asia Pharmaceutical Co's share price for today is ¥21.56.
Zhejiang East-Asia Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥10.09.

Zhejiang East-Asia Pharmaceutical Co EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Zhejiang East-Asia Pharmaceutical Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zhejiang East-Asia Pharmaceutical Co Ltd (SHSE:605177) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Laodong North Road, 23rd Floor, General Chamber of Commerce Building, Huangyan District, Zhejiang Province, Taizhou, CHN

Website

http://www.eapharm.cn

Zhejiang East-Asia Pharmaceutical Co Ltd is mainly engaged in the production of bulk pharmaceutical chemicals, tablets, granules and capsules. The company's main products are: Ofloxacin, levofloxacin, loratadine hydrochloride, levofloxacin hydrochloride, trimebutine maleate, ketoconazole, terbinafine hydrochloride, piperazine, ticlazole and so on.

Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) Headlines

No Headlines